Search

Your search keyword '"Sannareddy, Aishwarya"' showing total 38 results
Start Over Author "Sannareddy, Aishwarya"
38 results on '"Sannareddy, Aishwarya"'

1. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Jr., Larry D., and Lin, Yi

Published
2024
Full Text
View/download PDF

2. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

7. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

Author

Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz

Subjects
PLASMA exchange (Therapeutics), TREATMENT effectiveness, MULTIPLE myeloma, IMMUNOGLOBULIN light chains, KIDNEY diseases
Abstract

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Assessing the Predictive Value of Pre-Lymphodepletion and Infusion Endothelial Activation and Stress Index in CD19-Directed CAR-T Therapy for B-Cell Lymphoma

Author

Upreti, Harsh Vardhan, primary, Lee, Jimmy, additional, Sannareddy, Aishwarya, additional, Reves, Heather, additional, Turer, Laura, additional, Abraham, Pearl, additional, Liu, Yulun, additional, Yilmaz, Elif, additional, Wolfe, Heather, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan F., additional, Thiebaud, Julio Alvarenga, additional, Velarde, Alejandro Marino, additional, Collins, Robert H., additional, Chung, Stephen, additional, Geethakumari, Praveen Ramakrishnan, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, Afrough, Aimaz, additional, and Anderson, Julia Marie, additional

Published
2024
Full Text
View/download PDF

9. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis.

Author

Sannareddy, Aishwarya, primary, Lee, Jimmy, additional, Upreti, Harsh Vardhan, additional, Turer, Laura, additional, Anderson, Julia Marie, additional, Reves, Heather, additional, Gaines, Kailee, additional, Patel, Hetalkumari, additional, Abraham, Pearl, additional, Jones, Ashley, additional, Yn, Alicia, additional, Eze, Ebubechukwu, additional, Chong, Pearlie, additional, Tessier, Jeffrey, additional, Chung, Stephen, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Thiebaud, Julio Alvarenga, additional, Geethakumari, Praveen Ramakrishnan, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, La Hoz, Ricardo, additional, and Afrough, Aimaz, additional

Published
2024
Full Text
View/download PDF

10. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

11. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Peres, Lauren, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, Mehmet, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, McGuirk, Joseph, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Davis, James, additional, Kaur, Gurbakash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher, additional, Gaballa, Mahmoud, additional, Janakiram, Murali, additional, nadeem, omar, additional, Midha, Shonali, additional, Wagner, Charlotte, additional, Locke, Frederick, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

12. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Author

Dima, Danai, primary, Davis, James A., additional, Ahmed, Nausheen, additional, Jia, Xuefei, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

14. Abstract 5925: Prevalence of clonal hematopoiesis in patients with monoclonal gammopathy of undetermined significance

Author

Quaney, Vianey, primary, Kroger, Benjamin, additional, Sannareddy, Aishwarya, additional, Khan, Umar, additional, Kalkan, Fatma, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Huang, Yi, additional, Awan, Farrukh T., additional, Ramakrishnan, Praveen, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen S., additional, and Kaur, Gurbakhash, additional

Published
2023
Full Text
View/download PDF

15. ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, primary, Reves, Heather, additional, Narasimhan, Madhusudhanan, additional, Jaleta, Kefyalew, additional, Anderson, Julia Marie, additional, Patel, Hetalkumari, additional, Anderson, Larry D., additional, Afrough, Aimaz, additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran A, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Muthukumar, Alagar R, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

16. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, primary, Peres, Lauren, additional, Hashmi, Hamza, additional, Hosoya, Hitomi, additional, Ferreri, Christopher, additional, Atrash, Shebli, additional, Khouri, Jack, additional, Voorhees, Peter M., additional, Dima, Danai, additional, Simmons, Gary Lee, additional, Kalariya, Nilesh, additional, Hovanky, Vanna, additional, Bharadwaj, Sushma, additional, Arai, Sally, additional, Miklos, David B., additional, Wagner, Charlotte, additional, Davis, James, additional, Sborov, Douglas, additional, Nishihori, Taiga, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Gonzalez, Rebecca, additional, Kocoglu, Mehmet H., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, McGuirk, Joseph P., additional, Shune, Leyla, additional, Patel, Krina K., additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

17. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Author

Ferreri, Christopher J., primary, Hildebrandt, Michelle A.T., additional, Hashmi, Hamza, additional, Shune, Leyla O., additional, McGuirk, Joseph P., additional, Sborov, Douglas W., additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Khouri, Jack, additional, Dima, Danai, additional, Afrough, Aimaz, additional, Sannareddy, Aishwarya, additional, Simmons, Gary, additional, Davis, James, additional, Kalariya, Nilesh, additional, Peres, Lauren C., additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Sidana, Surbhi, additional, Hansen, Doris K., additional, Patel, Krina, additional, and Castaneda Puglianini, Omar Alexis, additional

Published
2022
Full Text
View/download PDF

18. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Author

Hashmi, Hamza, primary, Hansen, Doris K., additional, Peres, Lauren C., additional, Castaneda Puglianini, Omar Alexis, additional, Freeman, Ciara L., additional, De Avila, Gabriel, additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, Sborov, Douglas W., additional, Davis, James, additional, Wagner, Charlotte B., additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Simmons, Gary, additional, Ferreri, Christopher J., additional, Kalariya, Nilesh, additional, Sannareddy, Aishwarya, additional, Dima, Danai, additional, Khouri, Jack, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Patel, Krina, additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

19. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Author

Peres, Lauren C., primary, Oswald, Laura B., additional, Dillard, Christen, additional, De Avila, Gabriel, additional, Nishihori, Taiga, additional, Blue, Brandon J., additional, Freeman, Ciara L., additional, Locke, Frederick L., additional, Alsina, Melissa, additional, Castaneda Puglianini, Omar Alexis, additional, Shune, Leyla O., additional, Sborov, Douglas W., additional, Wagner, Charlotte B, additional, Dima, Danai, additional, Hashmi, Hamza, additional, Davis, James, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Simmons, Gary, additional, Kalariya, Nilesh, additional, Ferreri, Christopher J., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, Voorhees, Peter M., additional, Khouri, Jack, additional, McGuirk, Joseph P., additional, Sidana, Surbhi, additional, Hansen, Doris K., additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

20. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Author

Khouri, Jack, primary, Li, Hong, additional, Hansen, Doris K., additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, DeJarnette, Shaun, additional, Anwer, Faiz, additional, Sborov, Douglas W, additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Valent, Jason, additional, Peres, Lauren C., additional, Hovanky, Vanna, additional, Simmons, Gary, additional, Dima, Danai, additional, Kalariya, Nilesh, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher J., additional, Davis, James, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Hamilton, Betty K., additional, Alsina, Melissa, additional, Sauter, Craig S., additional, Hashmi, Hamza, additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

21. Prevalence of Clonal Hematopoiesis in Patients with Monoclonal Gammopathy of Undetermined Significance

Author

Quaney, Vianey, primary, Kroger, Benjamin, additional, Sannareddy, Aishwarya, additional, Khan, Umar, additional, Kalkan, Fatma, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Huang, Yi, additional, Awan, Farrukh T., additional, Ramakrishnan, Praveen, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen S., additional, and Kaur, Gurbakhash, additional

Published
2022
Full Text
View/download PDF

22. Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

Author

Sannareddy, Aishwarya, primary, Reves, Heather, additional, Jaleta, Kefyalew, additional, .Ramiahsankarasubramanian, Ramyakumari, additional, Patel, Hetalkumari, additional, Narasimhan, Madhusudhanan, additional, Anderson, Larry D., additional, Afrough, Aimaz, additional, Chung, Stephen S., additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran A, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T., additional, Muthukumar, Alagarraju, additional, and Ramakrishnan Geethakumari, Praveen, additional

Published
2022
Full Text
View/download PDF

23. Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Author

Sidana, Surbhi, primary, Peres, Lauren C., additional, Hashmi, Hamza, additional, Hosoya, Hitomi, additional, Ferreri, Christopher J., additional, Atrash, Shebli, additional, Khouri, Jack, additional, Voorhees, Peter M., additional, Dima, Danai, additional, Simmons, Gary, additional, Kalariya, Nilesh, additional, Hovanky, Vanna, additional, Bharadwaj, Sushma, additional, Arai, Sally, additional, Miklos, David B., additional, Wagner, Charlotte B, additional, Davis, James, additional, Sborov, Douglas W., additional, Nishihori, Taiga, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Gonzalez, Rebecca, additional, Kocoglu, M. Hakan, additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, McGuirk, Joseph P., additional, Shune, Leyla O., additional, Patel, Krina, additional, and Hansen, Doris K., additional

Published
2022
Full Text
View/download PDF

25. Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells

Author

Kansagra, Ankit, primary, Ramasamy, Dheepthi, additional, Sannareddy, Aishwarya, additional, Ding, Qing, additional, Wilden, Alexa, additional, Robinson, Cedric B, additional, Stephens, Helen, additional, Kalkan, Fatma, additional, Anderson Jr., Larry D., additional, Awan, Farrukh T, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Madanat, Yazan F., additional, Patel, Prapti, additional, Rizvi, Syed, additional, Ramakrishnan, Praveen, additional, Sweetenham, John W., additional, Vusirikala, Madhuri, additional, Agathocleous, Michalis, additional, and Chung, Stephen, additional

Published
2022
Full Text
View/download PDF

26. Pre-Lymphodepletion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in B-Cell Maturation Antigen CAR T Therapy for Multiple Myeloma

Author

Lee, Jimmy, Upreti, Harsh Vardhan, Sannareddy, Aishwarya, Reves, Heather, Turer, Laura, Abraham, Pearl, Liu, Yulun, Yilmaz, Elif, Wolfe, Heather, Kaur, Gurbakhash, Khan, Adeel, Madanat, Yazan F., Thiebaud, Julio Alvarenga, Velarde, Alejandro Marino, Collins, Robert H., Chung, Stephen, Geethakumari, Praveen Ramakrishnan, Awan, Farrukh T, Anderson, Larry D., Jr., Afrough, Aimaz, and Anderson, Julia Marie

Published
2024
Full Text
View/download PDF

27. T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy

Author

Tedone, Enzo, primary, Sayed, Mohammed, additional, Lai, Tsung-Po, additional, Sannareddy, Aishwarya, additional, P. Ramasamy, Dheepthi, additional, Anderson, Larry D., additional, Awan, Farrukh T., additional, Kaur, Gurbakhash, additional, Chung, Stephen, additional, Madanat, Yazan F., additional, Patel, Prapti, additional, Rizvi, Syed M, additional, Ramakrishnan, Praveen, additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, Sweetenham, John, additional, Shay, Jerry, additional, and Kansagra, Ankit, additional

Published
2021
Full Text
View/download PDF

28. Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells

Author

Kansagra, Ankit, primary, P. Ramasamy, Dheepthi, additional, Sannareddy, Aishwarya, additional, Ding, Qing, additional, Wilden, Alexa, additional, B. Robinson, Cedric, additional, Stephens, Helen, additional, Kalkan, Fatma, additional, Anderson, Larry D., additional, Awan, Farrukh T., additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Madanat, Yazan F., additional, Patel, Prapti, additional, Rizvi, Syed M, additional, Ramakrishnan, Praveen, additional, Sweetenham, John, additional, Vusirikala, Madhuri, additional, Agathocleous, Michalis, additional, and Chung, Stephen, additional

Published
2021
Full Text
View/download PDF

29. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Author

Sannareddy, Aishwarya, Turer, Laura, Lee, Jimmy, Gaines, Kailee, Patel, Hetalkumari, Abraham, Pearl, Jones, Ashley, Yn, Alicia, Eze, Ebubechukwu, Chong, Pearlie, Tessier, Jeffrey, Chung, Stephen S., Collins, Robert H., Madanat, Yazan F., Wolfe, Heather R, Yilmaz, Elif, Alvarenga Thiebaud, Julio, Ramakrishnan Geethakumari, Praveen, Kaur, Gurbakhash, Khan, Adeel, Anderson, Larry D., Jr., Awan, Farrukh T., La Hoz, Ricardo, and Afrough, Aimaz

Published
2023
Full Text
View/download PDF

33. P-111 Overall survival trends in young (

Author

Dong, Sharlene, Sannareddy, Aishwarya, Sankarasubramanian, Ramya, Reves, Heather, Khan, Umar, Sadeghi, Navid, Kainthla, Radhika, Khan, Adeel, Afrough, Aimaz, Wolfe, Heather, Madanat, Yazan, Geethakumari, Praveen Ramakrishnan, Yilmaz, Elif, Awan, Farrukh, Collins, Robert, Anderson, Larry, Li, Jenny, and Kaur, Gurbakhash

Published
2023
Full Text
View/download PDF

35. 436 - ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, Reves, Heather, Narasimhan, Madhusudhanan, Jaleta, Kefyalew, Anderson, Julia Marie, Patel, Hetalkumari, Anderson, Larry D., Jr., Afrough, Aimaz, Chung, Stephen, Collins, Robert H., Kaur, Gurbakhash, Kumar, Kiran A, Madanat, Yazan F., Vusirikala, Madhuri, Awan, Farrukh T, Muthukumar, Alagar R, and Geethakumari, Praveen Ramakrishnan

Published
2023
Full Text
View/download PDF

36. 42 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, Peres, Lauren, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Atrash, Shebli, Khouri, Jack, Voorhees, Peter M., Dima, Danai, Simmons, Gary Lee, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Arai, Sally, Miklos, David B., Wagner, Charlotte, Davis, James, Sborov, Douglas, Nishihori, Taiga, Alsina, Melissa, Locke, Frederick L., Gonzalez, Rebecca, Kocoglu, Mehmet H., Sannareddy, Aishwarya, Afrough, Aimaz, McGuirk, Joseph P., Shune, Leyla, Patel, Krina K., and Hansen, Doris K

Published
2023
Full Text
View/download PDF

37. 273 - Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells

Author

Kansagra, Ankit, Ramasamy, Dheepthi, Sannareddy, Aishwarya, Ding, Qing, Wilden, Alexa, Robinson, Cedric B, Stephens, Helen, Kalkan, Fatma, Anderson Jr., Larry D., Awan, Farrukh T, Collins, Robert H., Kaur, Gurbakhash, Madanat, Yazan F., Patel, Prapti, Rizvi, Syed, Ramakrishnan, Praveen, Sweetenham, John W., Vusirikala, Madhuri, Agathocleous, Michalis, and Chung, Stephen

Published
2022
Full Text
View/download PDF

38. Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Author

Dima, Danai, Sannareddy, Aishwarya, Ahmed, Nausheen, Davis, James A, Shaikh, Hira, Mahmoudjafari, Zahra, Duco, Marissa, Khouri, Jack, Kaur, Gurbakhash, Lochner, Jonathan, Anwer, Faiz, Afrough, Aimaz, Valent, Jason, Hashmi, Hamza, and Abdallah, Al-Ola

Abstract

Introduction:Older patients (>70 years old) are often considered ineligible for intensive treatments including autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR-T) therapies, having a relatively poor performance status and concomitant comorbidities. Therefore, the interest in this age group has been shifted in utilization of novel therapies with a less toxic side effect profile and less risk for serious complications. Teclistamab is a novel B-cell maturation antigen (BCMA)-directed bispecific antibody that received approval for the treatment of patients with RRMM after ≥4 prior lines of therapy (LOT) based on the results of the MajesTEC-1 trial. In this retrospective study, we aimed to analyze real-world data on the efficacy and toxicity profile of teclistamab in a population of older RRMM patients, and compare them with younger individuals.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results